Email Updates

You are here

Home»Media

AVAC in the News

  • Arm Implant to Prevent HIV in Reach

    A whip-thin length of polymer loaded with islatravir, Merck's investigational HIV prevention drug, and implanted into the arm is being investigated as a future option for people who have a hard time taking pills.

    July 24, 2019
    PrEP
    Medscape

  • 'Mosaic' Vax Proves Mettle Against More HIV Subtypes

    A "mosaic" vaccine against HIV was well-tolerated and able to produce an immune response against multiple clades, or disease subtypes, in healthy volunteers, a researcher said here.

    July 24, 2019
    HIV Vaccine
    MedPage Today

  • Someday, an Arm Implant May Prevent HIV Infection for a Year

    In what could eventually become a milestone for HIV prevention, very preliminary tests of an implant containing a new drug suggest that it may protect against infection for a full year. The new implant, by the drug company Merck, was tested in just a dozen subjects for 12 weeks. But experts were quite excited at its potential to revolutionize the long battle against HIV

    July 23, 2019
    PrEP
    New York Times

  • 'Potentially Game-Changing': PrEP Implant Shows Promise in Trial

    First in-human data found that an implant for pre-exposure prophylaxis (PrEP) for HIV prevention was safe and long-acting, according to a small phase I trial presented here.

    July 23, 2019
    PrEP
    MedPage Today

  • Large Scale HIV Vaccine Trial Announced, But PrEP May Challenge Enrollment

    In a major step forward for HIV vaccine research, the US research agency will partner with a pharmaceutical company on a large-scale, advanced-stage clinical study on an HIV vaccine. If the trial is successful, the vaccine may become the first ever to be approved for HIV prevention. But the rise of PrEP has created unexpected challenges to study enrollment.

    July 17, 2019
    HIV Vaccine, PrEP
    The BodyPro

  • J&J’s Quest for Elusive HIV Vaccine Is Poised for Major Test

    Johnson & Johnson is preparing to test an experimental HIV vaccine in the US and Europe in a move toward developing the first immunization against the deadly disease after decades of frustration. Some 3,800 men who have sex with men will receive a regimen of shots in a study that’s planned to be launched later this year, Anthony Fauci, director of the US National Institute of Allergy and Infectious Diseases, said in an interview. The agency and the HIV Vaccine Trials Network of testing sites will collaborate with J&J’s Janssen unit on the effort.

    July 12, 2019
    HIV Vaccine
    Bloomberg

  • PrEP Trials Offer Insight for Reaching at-Risk Women

    Reaching individuals at high risk of acquiring HIV infection continues to pose a challenge to uptake of HIV pre-exposure prophylaxis (PrEP). A new study looked at PrEP clinical trials in sub-Saharan Africa, examining recruitment strategies to reach women at high risk of contracting HIV.

    July 9, 2019
    PrEP
    Contagion Live

  • 25 Years of Uncertainty Over for Depo-Provera Users

    The debate on depo-provera increasing the risk of HIV acquisition started in 1996 when scientists discovered that monkeys injected with high concentration levels of depo-provera also known as DMPA by scientists had their biological make-up weakening, thereby allowing easy penetration of SIV, an equivalent of HIV in humans, into their system.

    June 25, 2019
    Hormonal Contraceptives and HIV
    The Herald

  • HIVR4P 2018: From Research to Impact Conference Summary and Highlights

    The HIV Research for Prevention (HIVR4P) conference is dedicated to advancing HIV prevention research, responding to a growing consensus that effective and durable prevention will require a combination of approaches as well as unprecedented collaboration among scientists, practitioners, and community workers from different fields and geographic areas. The conference theme in 2018, “From Research to Impact,” acknowledged an increasing focus on translation of promising research findings into practical, accessible, and affordable HIV prevention options for those who need them worldwide.

    May 29, 2019
    General
    AIDS Research and Human Retroviruses

  • Will a Vaccine Crisis of Confidence Impact the Global Response to HIV?

    The implications of the anti-vaccination movement are enormous. Just as vaccines against some of the greatest global killers finally come within reach, fear and misinformation could diminish vital commitments to continued vaccine research, and important investments in vaccine education and delivery. Effective vaccines might not get developed, manufactured, distributed or used due to misguided, anti-vaccine sentiment — potentially putting millions of people at risk for entirely preventable deaths and diseases.

    May 17, 2019
    HIV Vaccine
    Science Speaks

Pages